Loading...
•
Dec 31, 2023
Leap Therapeutics Q4 2023 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2023.
Key Takeaways
Leap Therapeutics reported its Q4 2023 financial results, highlighting advancements in DKN-01 and the integration of its pipeline. Enrollment is complete in Part C of the DisTinGuish study, with data expected mid-year.
Data from Part A of the DeFianCe study demonstrated a 30% overall response rate and a 93% disease control rate in second-line colorectal cancer patients.
Enrollment completed in Part C of the DisTinGuish study in first-line gastroesophageal junction and gastric cancer patients.
First randomized controlled data for DKN-01 expected starting in the middle of the year.
Company focused on delivering new personalized medicines to patients fighting against cancer.